Remove Government Remove Pharmaceuticals Remove Regulations
article thumbnail

Vanda-lay Litigation Industries, Inc.: Taking Stock of Vanda Pharmaceuticals, Inc.’s Big Bets on Petitioning and Litigation Against FDA and the Federal Government

FDA Law Blog: Biosimilars

Karst — If you monitor Regulations.gov dockets and litigation dockets on PACER like we do, then you know that one company name—more than any other over the past several years—pops up: Vanda Pharmaceuticals, Inc. VANDA PHARMACEUTICALS, INC. VANDA PHARMACEUTICALS, INC. 24-270 VANDA PHARMACEUTICALS, INC.

article thumbnail

UK life sciences can lead the way in cannabinoid R&D, says report

Drug Discovery World

The UK has the potential to become the global leader in pharmaceutical cannabinoid R&D, according to a new report published by the Cannabinoid Research and Development Group (CRDG). The report argues that pharmaceutical cannabinoid R&D is in danger of being held back in the UK by “inappropriately excessive” regulation.

Science 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UK Spring Budget a ‘vote of confidence’ in UK life sciences

Drug Discovery World

Additionally, a pledge to reform the regulation and approval of medicines, could see rapid approval for companies whose products have already gone through the US or European system and quickly open the UK as a new market.” We need regulation – but we need regulation that is focused on enabling solutions.”

Science 243
article thumbnail

The ABPI sets out a manifesto for UK life sciences

Drug Discovery World

The Association of the British Pharmaceutical Industry (ABPI) has published a manifesto outlining what a UK government must do to make the country a great place to research and develop the medicines and vaccines of the future.

Science 130
article thumbnail

EFPIA states AI rules must “enable not hinder” pharma R&D

Drug Discovery World

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has supported the use of artificial intelligence (AI) to deliver benefit for patients, life science companies and society, in response to the EU Artificial Intelligence (AI) Act.

article thumbnail

Partners develop oral ketamine-based antidepressant for home use

Drug Discovery World

MIRA Pharmaceuticals and MIRALOGX have formed a new partnership to develop and commercialise oral ketamine analog Ketamir-2, hoping to change the landscape of depressive disorder treatments. Ketamir-2 is a patent-pending compound under investigation to potentially deliver ultra-rapid antidepressant effects as early as four hours after dosing.

article thumbnail

NHS England launches country-wide cancer vaccine trials

Drug Discovery World

The vaccines being jointly developed by biopharmaceutical companies BioNTech and Genentech are still undergoing trials and have not yet been approved by regulators.

Vaccine 147